Genmab A/S (NASDAQ:GMAB) Trading 1.7% Higher – Still a Buy?

Genmab A/S (NASDAQ:GMAB)’s stock price rose 1.7% during trading on Friday . The stock traded as high as $21.00 and last traded at $20.93. Approximately 160,347 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 749,853 shares. The stock had previously closed at $20.58.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Truist Financial cut their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. Finally, Redburn Atlantic began coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Up 1.7 %

The firm has a market capitalization of $13.86 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. The business’s 50 day simple moving average is $21.60 and its two-hundred day simple moving average is $24.59.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the firm earned $0.47 earnings per share. As a group, equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently bought and sold shares of GMAB. Renaissance Technologies LLC boosted its holdings in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares during the period. Two Sigma Advisers LP grew its stake in shares of Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares in the last quarter. DDD Partners LLC purchased a new stake in Genmab A/S during the second quarter valued at approximately $8,860,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. Finally, FMR LLC increased its position in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after purchasing an additional 33,076 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.